Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-C11 pembrolizumab followed by chemotherapy in newly diagnosed classical Hodgkin lymphoma
MOH_2021-08-04_010187Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in classical Hodgkin lymphoma (cHL), sponsored by Merck & Co. Primary endpoint: Complete response rate at end of study treatment. Started Jul 2021; status: recruiting.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on MOH_2021-08-04_010187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-04_010187.